Treating Alzheimer's disease by targeting iron
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
No disease modifying drugs have been approved for Alzheimer's disease despite recent major investments by industry and governments throughout the world. The burden of Alzheimer's disease is becoming increasingly unsustainable, and given the last decade of clinical trial failures, a renewed understanding of the disease mechanism is called for, and trialling of new therapeutic approaches to slow disease progression is warranted. Here, we review the evidence and rational for targeting brain iron in Alzheimer's disease. Although iron elevation in Alzheimer's disease was reported in the 1950s, renewed interest has been stimulated by the advancement of fluid and imaging biomarkers of brain iron that predict disease progression, and the recent discovery of the iron‐dependent cell death pathway termed ferroptosis. We review these emerging clinical and biochemical findings and propose how this pathway may be targeted therapeutically to slow Alzheimer's disease progression. Linked Articles: This article is part of a themed section on Therapeutics for Dementia and Alzheimer's Disease: New Directions for Precision Medicine. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.18/issuetoc
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition
Doll, S., Proneth, B., Tyurina, Y. Y., Panzilius, E., Kobayashi, S., Ingold, I., Irmler, M., Beckers, J., Aichler, M., Walch, A., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2239 · Cited by 4,293
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 2×
“Crenezumab (Cummings et al., 2018) and aducanumab (Sevigny et al., 2016) are two additional antibodies that have shown target engagement in early studies and are currently undergoing testing in larger clinical trials.”
BackgroundA Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380 · cited 1×
“Vitamin E was shown to slow disease progression in patients with moderately severe AD over a 2‐year period (Sano et al., 1997), which was supported in a more recent clinical trial, which also demonstrated that patients with mild to moderate AD taking vitamin E had slowing of disease progression…”
ResultAutophagy promotes ferroptosis by degradation of ferritin
Hou, W., Xie, Y., Song, X., Sun, X., Lotze, M. T., Zeh, H. J., Kang, R., & Tang, D. (2016) · Autophagy · doi:10.1080/15548627.2016.1187366 · Cited by 2,332
Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis
Yang, W. S., Kim, K. J., Gaschler, M. M., Patel, M., Shchepinov, M. S., & Stockwell, B. R. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1603244113 · Cited by 2,329 · cited 1×
“Membrane phosphatidylethanolamines are vulnerable to peroxidation by specific iron‐dependent lipoxygenases (Yang et al., 2016): 5‐LOX (ALOX5), 12S‐LOX (ALOX12), 12R‐LOX (ALOX12B), 15‐LOX1 (ALOX15), 15‐LOX‐2 (ALOX15B), and E‐LOX (ALOXE3).”
BackgroundNelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050 · cited 1×
“The extent of tangle burden is more closely associated with cognitive decline than that of the extent of Aβ burden (Nelson et al., 2012).”
BackgroundTwo Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 1×
“On the basis of this, four Phase 3 trials commenced; two of the completed trials failed to show a clinical improvement, and the other trials were discontinued (Salloway et al., 2014).”
BackgroundFerroptosis is an autophagic cell death process
Gao, M., Monian, P., Pan, Q., Zhang, W., Xiang, J., & Jiang, X. (2016) · Cell Research · doi:10.1038/cr.2016.95 · Cited by 1,899
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844 · cited 1×
“However, a prior study showed no effect of vitamin E treatment in preventing conversion from mild cognitive imparment to AD over a 3‐year period (Petersen et al., 2005).”
BackgroundPhase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668 · cited 1×
“In two Phase 3 trials, solanezumab had no overall benefit to cognition; however, secondary analysis of a subgroup of mild AD patients that were pooled from both trials revealed a slowing of decline associated with treatment (Doody et al., 2014).”
BackgroundHolmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416 · cited 1×
“In extended analysis of the Phase I clinical trial of AN‐1792 that examined the brain of treated patients at autopsy, in the treatment group plaque was reduced or completely removed, but the cognitive presentation during life was not different between the groups (Holmes et al., 2008).”
BackgroundA Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049 · cited 1×
“This prompted a further Phase 3 trial of mild AD cases, where the drug had no impact on disease progression (Honig et al., 2018).”
BackgroundA phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753 · cited 1×
“…was also an antibody approach that proved effective in lowering Aβ burden in two Phase 2 studies (Rinne et al., 2010), and, although it had no overall effect on cognition, there appeared to be a treatment effect in people who did not express the APOE ε4 risk allele (Salloway et al., 2009).”
ResultRobinson, J. L., Lee, E. B., Xie, S. X., Rennert, L., Suh, E., Bredenberg, C., Caswell, C., Van Deerlin, V. M., Yan, N., Yousef, A., et al. (2018) · Brain · doi:10.1093/brain/awy146 · Cited by 729
Rinne, J. O., Brooks, D. J., Rossor, M. N., Fox, N. C., Bullock, R., Klunk, W. E., Mathis, C. A., Blennow, K., Barakos, J., Okello, A. A., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70043-0 · Cited by 701
Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease
Egan, M. F., Kost, J., Tariot, P. N., Aisen, P. S., Cummings, J. L., Vellas, B., Sur, C., Mukai, Y., Voss, T., Furtek, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1706441 · Cited by 685 · cited 1×
“However, a Phase 3 clinical trial showed no benefit to cognition despite lowering amyloid load (Egan et al., 2018).”
BackgroundDysken, M. W., Sano, M., Asthana, S., Vertrees, J. E., Pallaki, M., Llorente, M., Love, S., Schellenberg, G. D., McCarten, J. R., Malphurs, J., et al. (2014) · JAMA · doi:10.1001/jama.2013.282834 · Cited by 628
Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export
Lei, P., Ayton, S., Finkelstein, D. I., Spoerri, L., Ciccotosto, G. D., Wright, D. K., Wong, B. X. W., Adlard, P. A., Cherny, R. A., Lam, L. Q., et al. (2012) · Nature Medicine · doi:10.1038/nm.2613 · Cited by 594 · cited 2×
“Loss of tau was shown to prevent the presentation of APP at the cell surface (Lei et al., 2012), where it can act to stabilize the presentation of ferroprotein and promote iron export from the cell (Duce et al., 2010; McCarthy, Park, & Kosman, 2014; Wong et al., 2014).”
BackgroundSelf-citationA phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
for the SCarlet RoAD Investigators, Ostrowitzki, S., Lasser, R. A., Dorflinger, E., Scheltens, P., Barkhof, F., Nikolcheva, T., Ashford, E., Retout, S., Hofmann, C., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0318-y · Cited by 567 · cited 1×
“Gantenerumab, another Aβ immunotherapy, showed evidence of target engagement in a Phase 3 study, but an interim futility analysis halted the study early because of lack of clinical efficacy (Ostrowitzki et al., 2017).”
BackgroundRogers, J. T., Randall, J. D., Cahill, C. M., Eder, P. S., Huang, X., Gunshin, H., Leiter, L., McPhee, J., Sarang, S. S., Utsuki, T., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207435200 · Cited by 551 · cited 1×
“APP has a 5`UTR iron responsive element that suppresses translation of the protein in low iron conditions (Rogers et al., 2002).”
BackgroundSelf-citationYamamoto, A., Shin, R., Hasegawa, K., Naiki, H., Sato, H., Yoshimasu, F., & Kitamoto, T. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.t01-1-01061.x · Cited by 313
Raven, E. P., Lu, P. H., Tishler, T. A., Heydari, P., & Bartzokis, G. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130209 · Cited by 270
Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease
Ayton, S., Lei, P., Duce, J. A., Wong, B. X. W., Sedjahtera, A., Adlard, P. A., Bush, A. I., & Finkelstein, D. I. (2013) · Annals of Neurology · doi:10.1002/ana.23817 · Cited by 264
Self-citationReed, T., Perluigi, M., Sultana, R., Pierce, W. M., Klein, J. B., Turner, D. M., Coccia, R., Markesbery, W. R., & Butterfield, D. A. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.12.007 · Cited by 257 · cited 1×
“…AD brain (Bradley, Markesbery, & Lovell, 2010; Hajimohammadreza & Brammer, 1990; Markesbery, Kryscio, Lovell, & Morrow, 2005; Montine et al., 2001; Reed et al., 2008; Williams, Lynn, Markesbery, & Lovell, 2006), and increased levels of serum oxidative stress markers and shortfalls in serum…”
Controlled trial of N-acetylcysteine for patients with probable Alzheimer’s disease
Adair, J. C., Knoefel, J. E., & Morgan, N. (2001) · Neurology · doi:10.1212/wnl.57.8.1515 · Cited by 240
Increased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer disease
Bradley, M. A., Markesbery, W. R., & Lovell, M. A. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.02.016 · Cited by 193
Cortical iron reflects severity of Alzheimer's disease
van Duijn, S., Bulk, M., van Duinen, S. G., Nabuurs, R. J. A., van Buchem, M. A., van der Weerd, L., & Natté, R. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161143 · Cited by 172 · cited 1×
“…al., 2017; Bulk et al., 2018; Collingwood et al., 2005; Connor, Menzies, St Martin, & Mufson, 1992; De Reuck et al., 2014; Duce et al., 2010; Galazka‐Friedman et al., 2011; Goodman, 1953; Hallgren & Sourander, 1960; Smith et al., 2010; Smith, Harris, Sayre, & Perry, 1997; van Duijn et al., 2017).”
Motor and cognitive deficits in aged tau knockout mice in two background strains
Lei, P., Ayton, S., Moon, S., Zhang, Q., Volitakis, I., Finkelstein, D. I., & Bush, A. I. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-29 · Cited by 145
Self-citationMarked Age-Related Changes in Brain Iron Homeostasis in Amyloid Protein Precursor Knockout Mice
Belaidi, A. A., Gunn, A. P., Wong, B. X., Ayton, S., Appukuttan, A. T., Roberts, B. R., Duce, J. A., & Bush, A. I. (2018) · Neurotherapeutics · doi:10.1007/s13311-018-0656-x · Cited by 83
Self-citationAmyloid plaque-associated oxidative degradation of uniformly radiolabeled arachidonic acid
Furman, R., Murray, I. V. J., Schall, H. E., Liu, Q., Ghiwot, Y., & Axelsen, P. H. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00316 · Cited by 26 · cited 1×
“AD mouse models, supplemented with arachidonic acid (the major lipid substrate for ferroptosis), have been shown to be more prone to oxidation in the hippocampus compared with wild type mice (Furman et al., 2016).”
BackgroundKwiatek-Majkusiak, J., Dickson, D., Tacik, P., Aoki, N., Tomasiuk, R., Koziorowski, D., & Friedman, A. (2015) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2015-2044 · Cited by 25
Part, K., Künnis-Beres, K., Poska, H., Land, T., Shimmo, R., & Zetterström Fernaeus, S. (2015) · Brain Research · doi:10.1016/j.brainres.2015.09.034 · Cited by 16 · cited 1×
“Deferiprone is neuroprotective in neuronal culture models of Aβ toxicity (Molina‐Holgado, Gaeta, Francis, Williams, & Hider, 2008; Part et al., 2015), and it has been shown to reduce Aβ burden and tau phosphorylation in a rabbit model of AD (Prasanthi et al., 2012).”
Background
Cited by
Iron Homeostasis and Ferroptosis in Human Diseases: Mechanisms and Therapeutic Prospects
Ru, Q., Li, Y., Chen, L., Wu, Y., Min, J., & Wang, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01969-z · Cited by 724
Ferroptosis Mechanisms Involved in Neurodegenerative Diseases
Reichert, C. O., de Freitas, F. A., Sampaio-Silva, J., Rokita-Rosa, L., Barros, P. D. L., Levy, D., & Bydlowski, S. P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228765 · Cited by 422
Buccellato, F. R., D’Anca, M., Fenoglio, C., Scarpini, E., & Galimberti, D. (2021) · Antioxidants · doi:10.3390/antiox10091353 · Cited by 179
Pillaiyar, T., Meenakshisundaram, S., Manickam, M., & Sankaranarayanan, M. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112275 · Cited by 140
Selective ferroptosis vulnerability due to familial Alzheimer’s disease presenilin mutations
Greenough, M. A., Lane, D. J. R., Balez, R., Anastacio, H. T. D., Zeng, Z., Ganio, K., McDevitt, C. A., Acevedo, K., Belaidi, A. A., Koistinaho, J., et al. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-022-01003-1 · Cited by 102
Self-citation
Metadata
- Authors
- Nikseresht, S., Bush, A. I., & Ayton, S.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2019-02-11
- Volume
- 176
- Issue
- 18
- Pages
- 3622-3635
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2908881754
- Cited by
- 98
- References
- 38
- FWCI
- 8.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.